Guia prático de aerossolterapia na criança e no adolescente: Documento conjunto da Associação Brasileira de Alergia e Imunologia e Sociedade Brasileira de Pediatria
Practical guide to aerosol therapy in children and adolescents: Joint document from the Brazilian Association of Allergy and Immunology and the Brazilian Society of Pediatrics
Resumo
A via inalatória é a mais adequada para o tratamento das doenças respiratórias. Muitos fatores influenciam na deposição pulmonar do fármaco inalado, e, consequentemente, no sucesso terapêutico, desde fatores relacionados ao indivíduo, como questões anatômicas das vias aéreas, dinâmica respiratória, doença de base e técnica correta, até situações relacionadas às questões aerodinâmicas das partículas que compõem o aerossol, como o tamanho (diâmetro aerodinâmico mediano de massa) e a homogeneidade das partículas (desvio padrão geométrico). Nos últimos anos os dispositivos inalatórios se aperfeiçoaram, buscando atender às características necessárias que garantam uma deposição pulmonar satisfatória dos fármacos. A escolha do dispositivo inalatório deve ser individualizada, e o conhecimento das particularidades de cada dispositivo e das vantagens e desvantagens instrumentaliza o profissional na decisão, e impacta diretamente no sucesso terapêutico da medicação utilizada.
Palavras-chave
Abstract
The inhalation route is the most adequate for the treatment of respiratory diseases. Many factors influence pulmonary deposition of the inhaled drug and, consequently, therapeutic success. They include individual factors such as airway anatomy, respiratory dynamics, underlying disease, and correct technique, as well as factors related to the aerodynamics of aerosol particles such as size (mass median aerodynamic diameter) and homogeneity of the particles (geometric standard deviation). In recent years, inhalation devices have improved to comply with the necessary characteristics that guarantee a satisfactory pulmonary deposition of drugs. The choice of the inhalation device must be individualized, and the knowledge about the features of each device and their advantages and disadvantages instrumentalizes health professionals in the decision and impacts directly the therapeutic success of the medication used.
Keywords
Referências
1. Ravichandiran V, Masilamani K, Satheshkumar S, Joseprakash D. Drug delivery to the lungs. Int J Pharm Sci Rev Res. 2011;10(2):85-9.
2. Aguiar R, Lopes A, Ornelas C, Ferreira R, Caiado J, Mendes A, et al. Terapêutica inalatória: Técnicas de inalação e dispositivos inalatórios. Rev Port Imunoalergologia. 2017;25(1):9-26.
3. Pereira LFF. Como administrar drogas por via inalatória. J Pneumol. 1998;24:133-43.
4. Ariyananda PL, Agnew JE, Clarke SW. Aerosol delivery systems for bronchial asthma. Posgrad Med J. 1996;72:151-56.
5. Witek TJ Jr. The fate of inhaled drugs: the pharmacokinetics and pharmacodynamics of drugs administered by aerosol. Respir Care. 2000;45(7):826-30.
6. Feenstra TL, Rutten-Van Mölken MP, Jager JC, Van Essen-Zandvliet LE. Cost effectiveness of guideline advice for children with asthma: a literature review. Pediatr Pulmonol. 2002;34(6):442-54.
7. Skoner DP. Balancing safety and efficacy in pediatric asthma management. Pediatrics. 2002;109(2 Suppl):381-92.
8. Pandey Shivanand, Sweta B, Binal P, Mahalaxmi R, Viral D, Jivani P. Local and Systemic Pulmonary Drug Delivery of Small Molecules. J Pharm Res. 2009;2(8):1200-2.
9. Mortonen T, Yang Y. Deposition mechanics of pharmaceutical particles in human airways. In: Hickey AJ, ed. Inhalation Aerosols: Physical and Biological Basis for Therapy. New York: Marcel Dekker;1996. p. 1‑21.
10. Santos CIS, Rosa GJ, Shiratori AP, d’Aquino AG, Bueno, Okuro RT. Influência do choro e de padrões respiratórios na deposição de medicação inalatória em crianças. Rev Paul Pediatr. 2010;28(4):394-7.
11. Schüepp KG, Straub D, Möller A, Wildhaber JH. Deposition of aerosols in infants and children. J Aerosol Med. 2004;17:153-6.
12. Janssens HM, Tiddens HA. Aerosol therapy: the special needs of young children. Paediatr Respir Rev. 2006;7 (Suppl 1):S83-5.
13. Pauwels R, Newman S, Borgstrom L. Airway deposition and airway effects of antiasthma drugs delivered from metered-dose inhalers. Eur Respir J. 1997;10:2127-38.
14. Kleinstreuer C, Zhang Z, Donohue JF. Targeted drug-aerosol delivery in the human respiratory system. Annu Rev Biomed Eng. 2008;10:195‑220.
15. O’Callagan C, Barry PW. The science of nebulized drug delivery. Thorax. 1997;52(2):S31-S34.
16. Eixarch H, Haltner-Ukomadu E, Beisswenger C, Bock U. Drug delivery to the lung: permeability and physicochemical characteristics of drugs as the basis for a pulmonary biopharmaceutical classification system (pBCS). J Epith Biol Pharmacol. 2010;3(9):1-14.
17. Threlfall T. Crystallization of polymorphs: Thermodynamic insight into the role of solvent. Org Proc Res Dev. 2000;4(5):384-90.
18. Rabbani NR, Seville PC. The influence of formulation components on the aerosolisation properties of spray-dried powders. J Contr Release. 2005;110(1):130‑40.
19. Mansour HM, Rhee Y, Wu X. Nanomedicine in pulmonary delivery. Int J Nanomed. 2009;4:299-319.
20. Stein SW, Thiel CG. The History of Therapeutic Aerosols: a chronological review. J Aerossol Med Pulm Drug Deliv. 2017;30(1):20-40.
21. Cochrane M, Bala MV, Downs KE, Mauskopf J, Ben-Joseph RH. Inhaled corticosteroids for asthma therapy. Chest. 2000;117:542‑50.
22. Newman SP. Metered dose pressurized aerosols and the ozone layer. Eur Resp J. 1990;3(10):495-7.
23. Ram FS. Clinical efficacy of inhaler devices containing beta 2 agonist bronchodilators in the treatment of asthma: cochrane systematic review and meta-analysis of more than 100 randomized, controlled trials. Am J Respir Med. 2003;2:349-65.
24. Abreu S, Silva L, Teixeira S, Marques R, Ramalhete N, Antunes H. Avaliação do desempenho de três câmaras de expansão. Acta Med Port. 2012;25:4-9.
25. Amirav I, Newhouse MT, Luder A, Halamish A, Omar H, Gorenberg M.Feasibility of aerosol drug delivery to sleeping infants: a prospective observational study. BMJ Open. 2014;4:e004124.
26. Wildhaber JH, Janssens HM, Piérart F, Dore ND, Devadason SG, LeSouëf PN. High-percentage lung delivery in children from detergent-treated spacers. Pediatr Pulmonol. 2000;29:389-93.
27. Jones BE. A history of DPI capsule filling. Inhalation. 2009;3(3):20‑3.
28. Haidl P, Heindl S, Siemon K, Bernacka M, Cloes RM. Inhalation device requirements for patients' inhalation maneuvers. Resp Med. 2016;118:65-75.
29. McCallion ONM, Taylor KMG, Bridges PA, Thomas M, Taylor AJ. Jet nebulizers for pulmonary delivery. Int J Pharm. 1996;130:1-11.
30. Hess DR. Aerossol delivery devices in the treatment of asthma. Respir Care. 2008;54:699-725.
31. Hess DR. Nebulizers: principles and performance. Respir Care. 2000;45(6):609-22.
32. Fischer A, Stegemann J, Scheuch G, Siekmeier R. Novel devices for individualized controlled inhalation can optimize aerosol therapy in efficacy, patient care and power of clinical trials. Eur J Med Res. 2009;14(Sup.4):71‑7.
33. Ari A. Jet, ultrasonic, and mesh nebulizers: an evaluation of nebulizers for better clinical outcomes. Euras J Pulmonol. 2014;16:1-7.
34. Lass JS, Sant A, Knoch M. New advances in aerosolised drug delivery: vibrating membrane nebuliser technology. Expert Opin Drug Deliv. 2006 Sep;3(5):693-702.
35. Ehrmann S. Vibrating mesh nebulisers – can greater drug delivery to the airways and lungs improve respiratory outcomes? Eur Resp Pulm Dis. 2018;4(1):33-43.
36. Vecellio L. The mesh nebuliser: a recent technical innovation for aerosol delivery. Breathe. 2006;2(3):253-60.
37. Geller D. Comparing clinical features of the nebulizer, metered-dose inhaler, and dry powder inhaler. Respir Care. 2005;50:1313-21.
Submetido em:
15/06/2020
Aceito em:
22/06/2020
Facebook
Google+
Twitter
LinkedIn
Mendeley
StumbleUpon
CiteULike
Reddit
Email